| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 03/08/2002 | CA2357404A1 Method for growing or for removing circoviruses from biological material |
| 03/07/2002 | WO2002018954A2 Inhibition of cmv infection and dissemination |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018619A2 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |
| 03/07/2002 | WO2002018605A2 Anti-microbial agents |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018585A2 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018438A1 Modified proteins, isolated novel peptides, and uses thereof |
| 03/07/2002 | WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018380A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | WO2002018379A2 7-oxo pyridopyrimidines |
| 03/07/2002 | WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | WO2002018369A2 Peptidomimetic protease inhibitors |
| 03/07/2002 | WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | WO2002018354A1 Oxazolidinones and their use as antibacterial agents |
| 03/07/2002 | WO2002018353A2 Oxazolidinone chemotherapeutic agents |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018344A1 Novel ester or amide derivatives |
| 03/07/2002 | WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002018330A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| 03/07/2002 | WO2002018311A1 Process for the preparation of phenylphenol compounds |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017951A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | WO2002017945A1 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2002017938A1 Use of extracts of the cassia alata plant |
| 03/07/2002 | WO2002017935A2 A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017917A1 Manzamines for treatment of drug resistant infection |
| 03/07/2002 | WO2002017916A1 Antiviral and antimicrobial guanidine or biguanidine derivatives |
| 03/07/2002 | WO2002017915A1 Benzylidene thiazolidinediones and their use as antimycotic agents |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017900A2 Modulators of us28 (chemokines) for treating cytomegalovirus infections |
| 03/07/2002 | WO2002017854A2 Cephalosporin antibiotics and prodrugs thereof |
| 03/07/2002 | WO2002017732A2 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2001097750A3 Method for producing an antiviral agent |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001087329A8 Liquid pharmaceutical composition containing an erythropoietin derivate |
| 03/07/2002 | WO2001079269A3 Lipid binding protein 4 |
| 03/07/2002 | WO2001077181A3 Anti-rhesus d monoclonal antibodies |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001074855A3 Compositions and methods for dendritic cell-based immunotherapy |
| 03/07/2002 | WO2001072330A3 Method for immunostimulation using binding agents for the fc rec eptor of immunoglobulin a and for cancer cells or infections antigen |
| 03/07/2002 | WO2001068865A3 Fish vaccine against piscirickettsia salmonis |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001066551A3 Azole compounds as therapeutic agents for fungal infections |
| 03/07/2002 | WO2001064678A3 Inhibitors of hepatitis c virus ns3 protease |
| 03/07/2002 | WO2001059130A3 Proteins producing an altered immunogenic response and methods of making and using the same |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001058471A3 Novel amino acid and peptide inhibitors of staphylococcus virulence |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001055177A3 Methods to identify ctl epitopes of hiv |
| 03/07/2002 | WO2001055131A3 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 03/07/2002 | WO2001052824A3 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 03/07/2002 | WO2001046231A3 Polynucleotides and polypeptides encoded thereby |
| 03/07/2002 | WO2001044271A3 Daptomycin analogs and their use as antibacterial agents |
| 03/07/2002 | WO2001043761A3 Methods for treating and preventing damage to mucosal tissue |
| 03/07/2002 | WO2001041758A3 Valnemulin formulation |
| 03/07/2002 | WO2001040474A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 03/07/2002 | WO2001038360A3 Novel hcv non-structural polypeptide |
| 03/07/2002 | WO2001034184A3 Methods and compositions for protection against bovine herpesvirus 1 |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | US20020028973 Bactericides, antioxidants, and antiinflammatory agents |
| 03/07/2002 | US20020028943 For lowering serum lipid, cholesterol and/or triglyceride levels; treating atherosclerosis |
| 03/07/2002 | US20020028927 Substituted liposaccharides useful in the treatment and prevention of endotoxemia |
| 03/07/2002 | US20020028922 Chemically modified oligonucleotide for site-directed mutagenesis |
| 03/07/2002 | US20020028921 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 03/07/2002 | US20020028920 Processes for preparing clarithromycin polymorphs |
| 03/07/2002 | US20020028851 Guanylhydrazones and their use to treat inflammatory conditions |
| 03/07/2002 | US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides |
| 03/07/2002 | US20020028843 Mupirocin calcium amorphous as a microbiocide dissolved in a hydrophilic solvent, preferably, hexamethylene glycol; heat resistance; skin, ear and eye disorders; topical and nasal |
| 03/07/2002 | US20020028837 E.g., (2-(4-methoxyphenethyl))-N'-(2-(5-bromopyridyl))-thiourea; enzyme inhibitors of reverse transcriptase; viricides for HIV infection, including mutant, drug-sensitive, drug and multi-drug resistance strains |
| 03/07/2002 | US20020028826 HMG-CoA reductase inhibitors and method |
| 03/07/2002 | US20020028807 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl) oxy)ethyl)-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one for example; inhibitor of HIV replication; treating or preventing HIV infection |
| 03/07/2002 | US20020028803 Controlling cell apoptosis |
| 03/07/2002 | US20020028796 Adjustment mineral concentration |
| 03/07/2002 | US20020028784 Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| 03/07/2002 | US20020028781 Antibiotics |
| 03/07/2002 | US20020028771 Sulfonylation core antibiotic |
| 03/07/2002 | US20020028514 Recombinant AAV vector-based transduction system and use of same |
| 03/07/2002 | US20020028484 Expression vector for use in the treatment and prevention of viral diseases |
| 03/07/2002 | US20020028449 26 Human secreted proteins |
| 03/07/2002 | US20020028436 Suppression of leukocyte transferring in humans; administer immunoglobulins to humans, detect bound receptor, evaluate immune response |
| 03/07/2002 | US20020028211 Broad spectrum pyrogenic exotoxins antagonists and vaccines |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028190 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof |
| 03/07/2002 | DE10041428A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10041423A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10041238A1 Verfahren zur Identifizierung spezifisch spaltbarer peptide und Verwendung solcher Peptidsequenzen A method for identifying specific cleavable peptide and use of such peptide sequences |
| 03/07/2002 | DE10040933A1 Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen Use of beta-mannosylglycerate (firoin) and / or derivatives, in particular the beta-mannosylglyceramide (firoin-A), in cosmetic and dermatological formulations |
| 03/07/2002 | DE10040931A1 Verwendung von cyclischem 2,4 Diphosphoglycerat (cDGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen The use of cyclic 2,4 diphosphoglycerate (CDGP) and / or derivatives in cosmetic and dermatological formulations |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2731273A1 Processes and intermediates for preparing retroviral protease inhibitors |